Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.47)
# 306
Out of 5,055 analysts
66
Total ratings
61.7%
Success rate
18.91%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $13.71 | +45.88% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $71.25 | +6.67% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $10.88 | +28.68% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $23.71 | +30.75% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $15.70 | -42.68% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $26.46 | +24.72% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $149.00 | +27.52% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $91.06 | +9.82% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $19.11 | -0.58% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $377.98 | +3.18% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $66.39 | -17.16% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $96.48 | -42.99% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $144.52 | +10.71% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $567.16 | +18.13% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $6.66 | +200.30% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,388.96 | +0.79% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.57 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $41.77 | +115.47% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $220.44 | +22.48% | 4 | Dec 20, 2023 |
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.71
Upside: +45.88%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $71.25
Upside: +6.67%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $10.88
Upside: +28.68%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $23.71
Upside: +30.75%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $15.70
Upside: -42.68%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $26.46
Upside: +24.72%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $149.00
Upside: +27.52%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $91.06
Upside: +9.82%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $19.11
Upside: -0.58%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $377.98
Upside: +3.18%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $66.39
Upside: -17.16%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $96.48
Upside: -42.99%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $144.52
Upside: +10.71%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $567.16
Upside: +18.13%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $6.66
Upside: +200.30%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,388.96
Upside: +0.79%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $41.77
Upside: +115.47%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $220.44
Upside: +22.48%